(S)-(+)-N-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-2-chloro-acetamide | 1266784-40-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-(+)-N-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-2-chloro-acetamide
• 英文别名: (S)-(-)-N-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-2-chloro-acetamide；N-[(2S)-2-(5-bromo-2-fluorophenyl)-1-hydroxypropan-2-yl]-2-chloroacetamide
• CAS: 1266784-40-0
• 化学式: C₁₁H₁₂BrClFNO₂
• 分子量: 324.577
• InChiKey: YVZDFKILPGVRPA-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  rac-N-(2-(5-bromo-2-fluorophenyl)-1-hydroxypropan-2-yl)-2-chloroacetamide 以 二氯甲烷 为溶剂， 以The first eluting enantiomer (retention time: 9.94 min), the (S)-(−)-N-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-2-chloro-acetamide, was obtained as a light yellow waxy solid (1.05 g, 39% of theory)的产率得到(S)-(+)-N-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-2-chloro-acetamide
  参考文献：
  名称：

  3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES

  摘要：

  本发明涉及公式I的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁唑啉，具有BACE1和/或BACE2抑制活性，其制造，含有它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防例如阿尔茨海默病和2型糖尿病方面是有用的。

  公开号：

  US20120214806A1

文献信息

• 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS
  申请人：Banner David

  公开号：US20110312937A1

  公开（公告）日：2011-12-22

  This invention relates to compounds of the formula wherein A, B and R 1 to R 7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  这项发明涉及以下式的化合物 其中A、B和R1至R7如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢紊乱疾病的药物。
• 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES
  申请人：Andreini Matteo

  公开号：US20110046122A1

  公开（公告）日：2011-02-24

  The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的化学式I的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁嗪，以及它们的制备、含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗阿尔茨海默病和2型糖尿病等疾病方面具有用途。
• [EN] 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-AMINO-5-PHÉNYL-5,6-DIHYDRO-2H-[1,4]OXAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011020806A1

  公开（公告）日：2011-02-24

  The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[l,4]oxazine derivatives of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的式(I)的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁嗪衍生物，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗阿尔茨海默病和2型糖尿病等疾病方面是有用的。
• 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS
  申请人：Andreini Matteo

  公开号：US20120184540A1

  公开（公告）日：2012-07-19

  The present invention relates to 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的式I的1,4噁嗪，它们的制造，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病等疾病方面是有用的。
• [EN] 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS<br/>[FR] 1,4 OXAZINES UTILISÉS COMME INHIBITEURS DE BACE1 ET/OU BACE2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012098064A1

  公开（公告）日：2012-07-26

  The present invention relates to 1,4 Oxazines of formula (I): having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的式(I)的1,4噁嗪，它们的制备，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病方面是有用的。